Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PACD just gapped on the 30. Pincher on the weekly and monthly.
SCIE I'm still holding.
SCIE .001 X .0011 bid building and ask is getting hit
SCIE .001 X .0011 85M vol +22%
News came out today
http://www.marketwired.com/press-release/spectrascience-acquires-assets-of-oncoscope-otcqb-scie-2099356.htm
SOURCE: SpectraScience, Inc.
February 23, 2016 09:15 ET
SpectraScience Acquires Assets of Oncoscope
SAN DIEGO, CA--(Marketwired - February 23, 2016) - SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today that it has acquired the assets of Oncoscope, Inc. of Durham, North Carolina. Oncoscope developed a proprietary optical imaging system to provide immediate, minimally-invasive detection of pre-cancerous epithelial tissues using scattered white light. Their first target indication was for Barrett's Esophagus, a precursor for cancer of the esophagus.
"The Oncoscope technology is the perfect complement to ours. SpectraScience's Laser Induced Fluorescence Spectroscopy (LIFS) measures concentration of specific biomarkers in epithelial tissues. The strength of Oncoscope's technology is its focus on enlarged cell nuclei, an early marker of pre-cancers and cancers. Both technologies arrive at the same conclusion by measuring different indicators. Having two complementary technologies allows us to address multiple types of cancers including both esophageal and colon cancers," said Michael Oliver, President and Chief Executive Officer of SpectraScience. He went on to say, "Oncoscope's focus on a diagnostic for Barrett's Esophagus will shorten the development time for a commercial product to address this indication. With a solution for diagnosis of cancer in the upper GI as well as the lower GI, we will be able to more efficiently utilize our manufacturing capabilities and leverage the sales channel to Gastroenterologists."
About SpectraScience, Inc.:
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. Protected by more than 30 patents in 28 countries, covering fundamental elements of the technology, the WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative patent protected technology for clinical use.
For more information:
Visit our web site www.spectrascience.com
Forward-Looking Statement for SpectraScience, Inc.
This news release contains forward-looking statements that involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.
Contact Information
Contacts:
Media and Investors:
SpectraScience, Inc.
Lowell Giffhorn
CFO
Phone: (858) 847-0200 x2019
Email: lgiffhorn@spectrascience.com
News came out today.
SpectraScience Acquires Assets of Oncoscope
SAN DIEGO, CA--(Marketwired - February 23, 2016) - SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today that it has acquired the assets of Oncoscope, Inc. of Durham, North Carolina. Oncoscope developed a proprietary optical imaging system to provide immediate, minimally-invasive detection of pre-cancerous epithelial tissues using scattered white light. Their first target indication was for Barrett's Esophagus, a precursor for cancer of the esophagus.
"The Oncoscope technology is the perfect complement to ours. SpectraScience's Laser Induced Fluorescence Spectroscopy (LIFS) measures concentration of specific biomarkers in epithelial tissues. The strength of Oncoscope's technology is its focus on enlarged cell nuclei, an early marker of pre-cancers and cancers. Both technologies arrive at the same conclusion by measuring different indicators. Having two complementary technologies allows us to address multiple types of cancers including both esophageal and colon cancers," said Michael Oliver, President and Chief Executive Officer of SpectraScience. He went on to say, "Oncoscope's focus on a diagnostic for Barrett's Esophagus will shorten the development time for a commercial product to address this indication. With a solution for diagnosis of cancer in the upper GI as well as the lower GI, we will be able to more efficiently utilize our manufacturing capabilities and leverage the sales channel to Gastroenterologists."
About SpectraScience, Inc.:
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. Protected by more than 30 patents in 28 countries, covering fundamental elements of the technology, the WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative patent protected technology for clinical use.
For more information:
Visit our web site www.spectrascience.com
Forward-Looking Statement for SpectraScience, Inc.
This news release contains forward-looking statements that involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.
Contacts:
Media and Investors:
SpectraScience, Inc.
Lowell Giffhorn
CFO
Phone: (858) 847-0200 x2019
Email: lgiffhorn@spectrascience.com
(MORE TO FOLLOW) Dow Jones Newswires
February 23, 2016 09:15 ET (14:15 GMT)
SCIE news:
SpectraScience Acquires Assets of Oncoscope
SAN DIEGO, CA--(Marketwired - February 23, 2016) - SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today that it has acquired the assets of Oncoscope, Inc. of Durham, North Carolina. Oncoscope developed a proprietary optical imaging system to provide immediate, minimally-invasive detection of pre-cancerous epithelial tissues using scattered white light. Their first target indication was for Barrett's Esophagus, a precursor for cancer of the esophagus.
"The Oncoscope technology is the perfect complement to ours. SpectraScience's Laser Induced Fluorescence Spectroscopy (LIFS) measures concentration of specific biomarkers in epithelial tissues. The strength of Oncoscope's technology is its focus on enlarged cell nuclei, an early marker of pre-cancers and cancers. Both technologies arrive at the same conclusion by measuring different indicators. Having two complementary technologies allows us to address multiple types of cancers including both esophageal and colon cancers," said Michael Oliver, President and Chief Executive Officer of SpectraScience. He went on to say, "Oncoscope's focus on a diagnostic for Barrett's Esophagus will shorten the development time for a commercial product to address this indication. With a solution for diagnosis of cancer in the upper GI as well as the lower GI, we will be able to more efficiently utilize our manufacturing capabilities and leverage the sales channel to Gastroenterologists."
About SpectraScience, Inc.:
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. Protected by more than 30 patents in 28 countries, covering fundamental elements of the technology, the WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative patent protected technology for clinical use.
For more information:
Visit our web site www.spectrascience.com
Forward-Looking Statement for SpectraScience, Inc.
This news release contains forward-looking statements that involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.
Contacts:
Media and Investors:
SpectraScience, Inc.
Lowell Giffhorn
CFO
Phone: (858) 847-0200 x2019
Email: lgiffhorn@spectrascience.com
(MORE TO FOLLOW) Dow Jones Newswires
February 23, 2016 09:15 ET (14:15 GMT)
RXMD .03...bid building
CPST on the move
Appears that way and then a little panic selling. Still learning? Aha, me too, it'll never end. :)
Or possibly closing a gap.
My dates are off in regards to my explanation of the inside cup and handle. I was looking at the weekly. No time to fix. I'm heading out for the day.......GOOOO TPAC!!!!
Yes, I agree, charting does leave room for interpretation. I tend to lump patterns into categories. And, of course, hardly any pattern will ever meet all the criteria written and agreed upon, in popular books. Especially in pinky land. IMO, this does not invalidate the move. It might change the math that should be applied to a "valid" cup and handle. But the patterns are similar.
I would also consider there to be an inside cup with a long handle that started on 3/16 and formed the right lip on 6/15 and turned into a saucer consolidation on the handle and broke out of the pattern on 12/7. I know it isn't one but I tend to lump these patterns into categories. And since no pattern is ever perfect, and we are trading pinks, I tend to leave room for leeway. It makes it easy to spot patterns when scanning.
I suppose you are right. I shouldn't make claims like this unless the patterns match up with what is considered to be a valid pattern.
What's most important to me is which way the pattern breaks out. I agree with both you and Georgie, .007 will be some resistance and also we could easily see .01 this week. But, we gotta break that .0065 area first.
TPAC .0065 would be the breakout point of the cup and handle. imo
TPAC .0053 X .0054 +22.73% L2 looking thin
TPAC looking good. I'm all loaded up.
BBRD up 22%
Picked up a few TPAC .0045s up
Nice board, marked #263
Have a safe and happy new year all you chart pornist.....See ya in 2016!!!
Thanks for the chart Strong. Plenty of room to run.
BBRD on the move
AXXE going .0021s getting hit
BBRD looks ready
Picked up a few here today.....
JustaFew
Looking for a break and hold @.004......maybe not gonna happen though.....keeping on watchlist
not looking so hot now......VFIN on the ask....on watchlist
CDII nice move today
CDII looking good
Nice hammer forming on the daily....looking good here.
Absolutely best post of the week. You can't have a cup and handle without a handle. So many emotional traders around here that aren't aware of how stocks trade. In context of the trading pattern, we are right on track. Good eye taztooz :)
Free L2 on otcmarkets
http://www.otcmarkets.com/stock/PUGE/quote
umm....I"m not sure how this is relevant to my post.